 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|||||||||||||||
 |
 |
 |
|
|||||||||||||
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|||
 |
|
|||||||||||||||
 |
|
|||||||||||||||
|
|
|
|
|
|
|
|
|
|
 |
|
||||||||
Letter to ShareholdersApril 16, 2012 Dear Fellow Shareholders, Several of you have expressed a desire to understand our recently announced registered direct financing. The financing provided gross proceeds of $5.54 million from the sale of 6,517,648 shares of common stock for $0.85 per share, together with six-year Series A warrants to purchase 6,517,648 shares for $1.15 per share and short-term Series B warrants to purchase 6,617,648 shares for $0.85 per share. The Series B warrants have the potential to provide an additional $5.54 million in capital prior to their expiration in mid-October. There are also approximately 6.6 million warrants outstanding with an exercise price of $2 each that were issued in 2007 and are set to expire in December 2012. Continue reading » »
|
|||||||||
Titan Pharmaceuticals Announces First Quarter 2012 Financial ResultsTuesday, May 16, 2012 - 10:00AM PT | 1:00pm ETParticipant Toll Free: 888-329-8877 | Participant Passcode: 4735113 THE EVENT/REGISTRATION PAGE URL FOR THE WEBCAST IS: http://www.visualwebcaster.com/event.asp?id=87211 |
|||||||||
 |
|
||||||||
 |
 |
 |
|
||||||
 |
 |
 |
SOUTH SAN FRANCISCO, CA May 11, 2012 – Titan Pharmaceuticals, Inc. (TTNP.OB) today reported financial results for the first quarter ended March 31, 2012. Total revenues for the first quarter were approximately $1.3 million, compared to $0.9 million for the comparable period in 2011. First quarter 2012 revenues consisted primarily of $1.2 million in royalties on net sales of Fanapt®, which will be paid by Titan to Deerfield Management Company L.P. in accordance with the terms of the agreements entered into during 2011. First quarter 2012 revenues also included $42,000 in grant revenues from the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) grant for Titan’s proprietary ProNeura™ drug delivery technology. SOUTH SAN FRANCISCO, CA May 9, 2012 – Titan Pharmaceuticals, Inc. (TTNP.OB) today announced that it will host a live conference call at 1 p.m. ET / 10 a.m. PT on Wednesday, May 16, 2012. Titan will provide the Company’s financial results as of March 31, 2012 and an update on the Probuphine program. The call will be hosted by Sunil Bhonsle, President, Katherine Beebe, Ph.D., Executive Vice President and Chief Development Officer, Brian Crowley, Vice President of Finance and Marc Rubin, M.D., Executive Chairman. SOUTH SAN FRANCISCO, CA April 20, 2012 – Titan Pharmaceuticals, Inc. (TTNP.OB) today announced that positive efficacy and safety results from its confirmatory Phase 3 clinical trial evaluating Probuphine® in patients with opioid dependence will be presented during a poster presentation at the American Society of Addiction Medicine (ASAM) 43rd Medical-Scientific Conference being held April 19-22, 2012 in Atlanta. SOUTH SAN FRANCISCO, CA April 10, 2012 – Titan Pharmaceuticals, Inc. (TTNP.OB) today announced that it has entered into definitive agreements to sell approximately $5.5 million of shares of its common stock and warrants to purchase shares of its common stock in a registered direct offering to institutional investors. 
|
 |
 |
 |
|
||
 |
 |
|
|||||||
Fanapt® (iloperidone)
On May 6, 2009 Fanapt, an atypical antipsychotic drug, was granted marketing approval by the US Food & Drug Administra-tion for the treatment of adult patients with schizophrenia. More... » »
Probuphine™
Probuphine is a novel, subcutaneous implant formulation of buprenorphine designed to deliver six months of medication following a single treatment. This product is in Phase 3 development and has already demonstrated strong positive results... More... » » |
Titan Pharmaceuticals, Inc. is a biopharmaceutical company with valuable assets in the CNS (central nervous system) area. On May 6, 2009, US Food & Drug Administration granted marketing approval to Fanapt® (iloperi-done) for the treatment of adult patients with schizophrenia. This milestone represents the first marketing approval for a product out-licensed by Titan. The global sales from atypical antipsycho-tics, the same class of drugs like Fanapt®, exceeded $20 billion in 2007. Titan is entitled to receive 8-10% of global annual sales as royalty revenue, which may commence as early as the end of 2009. Read more... » » | |
|||||||